Back

MDS-associated SF3B1 mutations promote aberrant fate choice of hematopoietic stem cell via mis-splicing of mediator kinase module component CDK8

Bonner, E. A.; Hsueh, T.-Y.; Song, A.; Arriaga-Gomez, E. A.; Venkataraman, R.; Sinha, S.; Nguyen, E.; Ferrell, P. B.; Welner, R. S.; Lu, R.; Stirewalt, D. L.; Doulatov, S.; Lee, S. C.

2025-08-19 cancer biology
10.1101/2025.08.14.670174 bioRxiv
Show abstract

Mutations in RNA splicing factor SF3B1 are among the most common in MDS and are strongly associated with MDS with ring sideroblasts (MDS-RS). While aberrant splicing of terminal erythroid regulators has been implicated in MDS pathogenesis, the impact of SF3B1 mutations on early hematopoietic progenitor function remains unclear. Here, we identify CDK8, a key kinase of the mediator complex involved in transcriptional regulation, as a recurrent mis-spliced target in SF3B1-mutant MDS. Mutant SF3B1 induces cryptic 3' splice site selection in CDK8, leading to loss of CDK8 mRNA and protein. Using primary human HSPCs, our study identifies CDK8 as an important regulator of HSPC homeostasis and cell fate determination. CDK8 depletion results in expansion of HSPCs and shifts differentiation toward the erythroid and myeloid lineages, mirroring phenotypes observed in SF3B1-mutant MDS. Lastly, functional restoration of CDK8 rescues early erythroid phenotypes in SF3B1-mutant cells. These findings implicate CDK8 mis-splicing as a mechanistic driver of altered progenitor fate and dysplasia in SF3B1-mutant MDS, linking aberrant splicing to transcriptional dysregulation and hematopoietic lineage commitment.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Blood
67 papers in training set
Top 0.1%
40.5%
2
Haematologica
24 papers in training set
Top 0.1%
7.0%
3
Nature Communications
4913 papers in training set
Top 28%
6.5%
50% of probability mass above
4
Leukemia
39 papers in training set
Top 0.2%
5.0%
5
Blood Advances
54 papers in training set
Top 0.3%
5.0%
6
Journal of Experimental Medicine
106 papers in training set
Top 1%
3.3%
7
Experimental Hematology
11 papers in training set
Top 0.1%
3.2%
8
Journal of Clinical Investigation
164 papers in training set
Top 1%
3.2%
9
Cancer Discovery
61 papers in training set
Top 0.8%
2.7%
10
Cell Reports
1338 papers in training set
Top 22%
1.9%
11
JCI Insight
241 papers in training set
Top 3%
1.7%
12
eLife
5422 papers in training set
Top 46%
1.4%
13
Science Translational Medicine
111 papers in training set
Top 4%
1.0%
14
Cell Death & Disease
126 papers in training set
Top 2%
0.8%
15
Clinical Epigenetics
53 papers in training set
Top 0.9%
0.8%
16
Molecular Cancer Research
42 papers in training set
Top 0.7%
0.8%
17
Genome Medicine
154 papers in training set
Top 8%
0.8%
18
Nature Cancer
35 papers in training set
Top 1%
0.7%
19
Cell Reports Medicine
140 papers in training set
Top 9%
0.7%
20
Cancers
200 papers in training set
Top 5%
0.7%
21
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 48%
0.5%
22
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.5%
23
Oncogene
76 papers in training set
Top 2%
0.5%
24
Cell Death & Differentiation
48 papers in training set
Top 1%
0.5%
25
Science Advances
1098 papers in training set
Top 34%
0.5%
26
Clinical Cancer Research
58 papers in training set
Top 2%
0.5%